Mechanisms of action for the medium-chain triglyceride ketogenic diet in neurological and metabolic disorders

The Lancet Neurology

Volumn 17, Issue 1, 2018, Pages 84-93

  Augustin, Katrin ^a   Khabbush, Aziza ^b   Williams, Sophie ^c   Eaton, Simon ^b   Orford, Michael ^b   Cross, J Helen ^b   Heales, Simon J R ^b   Walker, Matthew C ^c   Williams, Robin S B ^a  

^a UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GLUTAMATE RECEPTOR; KETONE; MEDIUM CHAIN TRIACYLGLYCEROL; DECANOIC ACID; DECANOIC ACID DERIVATIVE; OCTANOIC ACID; OCTANOIC ACID DERIVATIVE;

ALZHEIMER DISEASE; CANCER INHIBITION; CELL ENERGY; EPILEPSY; HUMAN; INSULIN RESISTANCE; KETOGENIC DIET; METABOLIC DISORDER; MITOCHONDRIAL BIOGENESIS; NEUROLOGIC DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; REVIEW; SEIZURE THRESHOLD; DIABETES MELLITUS; DIET THERAPY; METABOLISM; NEOPLASM; PROCEDURES; SEIZURE;

ALZHEIMER DISEASE; CAPRYLATES; DECANOIC ACIDS; DIABETES MELLITUS; DIET, KETOGENIC; HUMANS; NEOPLASMS; SEIZURES;

EID: 85039561553     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(17)30408-8     Document Type: Review

References (100)

1. Martin, K, Jackson, CF, Levy, RG, Cooper, PN, Ketogenic diet and other dietary treatments for epilepsy. Cochrane Database Syst Rev, 2, 2016 CD001903.
2. Neal, E, “Alternative” ketogenic diets. Masino, SA, (eds.) Ketogenic diet and metabolic therapies, 2017, Oxford University Press, New York, 5–15.
3. Ye, F, Li, XJ, Jiang, WL, Sun, HB, Liu, J, Efficacy of and patient compliance with a ketogenic diet in adults with intractable epilepsy: a meta-analysis. J Clin Neurol 11 (2015), 26–31.
4. Lambrechts, DA, Wielders, LH, Aldenkamp, AP, Kessels, FG, de Kinderen, RJ, Majoie, MJ, The ketogenic diet as a treatment option in adults with chronic refractory epilepsy: efficacy and tolerability in clinical practice. Epilepsy Behav 23 (2012), 310–314.
5. Croteau, E, Castellano, CA, Fortier, M, et al. A cross-sectional comparison of brain glucose and ketone metabolism in cognitively healthy older adults, mild cognitive impairment and early Alzheimer's disease. Exp Gerontol, 2017 published online July 12. DOI:10.1016/j.exger.2017.07.004.
6. Courchesne-Loyer, A, Croteau, E, Castellano, CA, St-Pierre, V, Hennebelle, M, Cunnane, SC, Inverse relationship between brain glucose and ketone metabolism in adults during short-term moderate dietary ketosis: a dual tracer quantitative positron emission tomography study. J Cereb Blood Flow Metab 37 (2017), 2485–2493.
7. Castellano, CA, Nugent, S, Paquet, N, et al. Lower brain 18F-fluorodeoxyglucose uptake but normal 11C-acetoacetate metabolism in mild Alzheimer's disease dementia. J Alzheimers Dis 43 (2015), 1343–1353.
8. Klement, RJ, Champ, CE, Otto, C, Kammerer, U, Anti-tumour effects of ketogenic diets in mice: a meta-analysis. PLoS One, 11, 2016, e0155050.
9. Abdelwahab, MG, Fenton, KE, Preul, MC, et al. The ketogenic diet is an effective adjuvant to radiation therapy for the treatment of malignant glioma. PLoS One, 7, 2012, e36197.
10. Jansen, N, Walach, H, The development of tumours under a ketogenic diet in association with the novel tumour marker TKTL1: a case series in general practice. Oncol Lett 11 (2016), 584–592.
11. Scheck, AC, Abdelwahab, MG, Fenton, KE, Stafford, P, The ketogenic diet for the treatment of glioma: insights from genetic profiling. Epilepsy Res 100 (2012), 327–337.
12. Poff, AM, Ari, C, Seyfried, TN, D'Agostino, DP, The ketogenic diet and hyperbaric oxygen therapy prolong survival in mice with systemic metastatic cancer. PLoS One, 8, 2013, e65522.
13. Geng, S, Zhu, W, Xie, C, et al. Medium-chain triglyceride ameliorates insulin resistance and inflammation in high fat diet-induced obese mice. Eur J Nutr 55 (2016), 931–940.
14. Mumme, K, Stonehouse, W, Effects of medium-chain triglycerides on weight loss and body composition: a meta-analysis of randomized controlled trials. J Acad Nutr Diet 115 (2015), 249–263.
15. Puchalska, P, Crawford, PA, Multi-dimensional roles of ketone bodies in fuel metabolism, signaling, and therapeutics. Cell Metab 25 (2017), 262–284.
16. Likhodii, SS, Musa, K, Mendonca, A, Dell, C, Burnham, WM, Cunnane, SC, Dietary fat, ketosis, and seizure resistance in rats on the ketogenic diet. Epilepsia 41 (2000), 1400–1410.
17. Thavendiranathan, P, Mendonca, A, Dell, C, et al. The MCT ketogenic diet: effects on animal seizure models. Exp Neurol 161 (2000), 696–703.
18. Chang, P, Augustin, K, Boddum, K, et al. Seizure control by decanoic acid through direct AMPA receptor inhibition. Brain 139 (2016), 431–443.
19. Dallerac, G, Moulard, J, Benoist, JF, et al. Non-ketogenic combination of nutritional strategies provides robust protection against seizures. Sci Rep, 7, 2017, 5496.
20. Chang, P, Terbach, N, Plant, N, Chen, PE, Walker, MC, Williams, RS, Seizure control by ketogenic diet-associated medium chain fatty acids. Neuropharmacology 69 (2013), 105–114.
21. Chang, P, Zuckermann, AM, Williams, S, et al. Seizure control by derivatives of medium chain fatty acids associated with the ketogenic diet show novel branching-point structure for enhanced potency. J Pharmacol Exp Ther 352 (2015), 43–52.
22. Chang, P, Orabi, B, Deranieh, RM, et al. The anti-epileptic valproic acid and other medium chain fatty acids acutely reduce phosphoinositide levels independently of inositol in dictyostelium. Dis Model Mech 5 (2012), 115–124.
23. Hughes, SD, Kanabus, M, Anderson, G, et al. The ketogenic diet component decanoic acid increases mitochondrial citrate synthase and complex I activity in neuronal cells. J Neurochem 129 (2014), 426–433.
24. Schonfeld, P, Wojtczak, L, Short- and medium-chain fatty acids in energy metabolism: the cellular perspective. J Lipid Res 57 (2016), 943–954.
25. Wlaz, P, Socala, K, Nieoczym, D, et al. Acute anticonvulsant effects of capric acid in seizure tests in mice. Prog Neuropsychopharmacol Biol Psychiatry 57 (2015), 110–116.
26. Wlaz, P, Socala, K, Nieoczym, D, et al. Anticonvulsant profile of caprylic acid, a main constituent of the medium-chain triglyceride (MCT) ketogenic diet, in mice. Neuropharmacology 62 (2012), 1882–1889.
27. Thevenet, J, De Marchi, U, Domingo, JS, et al. Medium-chain fatty acids inhibit mitochondrial metabolism in astrocytes promoting astrocyte-neuron lactate and ketone body shuttle systems. FASEB J 30 (2016), 1913–1926.
28. Dienel, GA, Brain lactate metabolism: the discoveries and the controversies. J Cereb Blood Flow Metab 32 (2012), 1107–1138.
29. Khabbush, A, Orford, M, Tsai, YC, et al. Neuronal decanoic acid oxidation is markedly lower than that of octanoic acid: a mechanistic insight into the medium-chain triglyceride ketogenic diet. Epilepsia 58 (2017), 1423–1429.
30. White, H, Venkatesh, B, Clinical review: ketones and brain injury. Crit Care, 15, 2011, 219.
31. Simeone, TA, Simeone, KA, Rho, JM, Ketone bodies as anti-seizure agents. Neurochem Res 42 (2017), 2011–2018.
32. Kass, HR, Winesett, SP, Bessone, SK, Turner, Z, Kossoff, EH, Use of dietary therapies amongst patients with GLUT1 deficiency syndrome. Seizure 35 (2016), 83–87.
33. Mantis, JG, Meidenbauer, JJ, Zimick, NC, Centeno, NA, Seyfried, TN, Glucose reduces the anticonvulsant effects of the ketogenic diet in EL mice. Epilepsy Res 108 (2014), 1137–1144.
34. Lutas, A, Yellen, G, The ketogenic diet: metabolic influences on brain excitability and epilepsy. Trends Neurosci 36 (2013), 32–40.
35. Donevan, SD, White, HS, Anderson, GD, Rho, JM, Voltage-dependent block of N-methyl-D-aspartate receptors by the novel anticonvulsant dibenzylamine, a bioactive constituent of L-(+)-beta-hydroxybutyrate. Epilepsia 44 (2003), 1274–1279.
36. Yang, L, Zhao, J, Milutinovic, PS, Brosnan, RJ, Eger, EI, Sonner, JM, Anesthetic properties of the ketone bodies beta-hydroxybutyric acid and acetone. Anesth Analg 105 (2007), 673–679.
37. Juge, N, Gray, JA, Omote, H, et al. Metabolic control of vesicular glutamate transport and release. Neuron 68 (2010), 99–112.
38. Kadowaki, A, Sada, N, Juge, N, Wakasa, A, Moriyama, Y, Inoue, T, Neuronal inhibition and seizure suppression by acetoacetate and its analog, 2-phenylbutyrate. Epilepsia 58 (2017), 845–857.
39. Kim do, Y, Simeone, KA, Simeone, TA, et al. Ketone bodies mediate antiseizure effects through mitochondrial permeability transition. Ann Neurol 78 (2015), 77–87.
40. Masino, SA, Li, T, Theofilas, P, et al. A ketogenic diet suppresses seizures in mice through adenosine A(1) receptors. J Clin Invest 121 (2011), 2679–2683.
41. Kim, DY, Abdelwahab, MG, Lee, SH, et al. Ketones prevent oxidative impairment of hippocampal synaptic integrity through KATP channels. PLoS One, 10, 2015, e0119316.
42. Sada, N, Lee, S, Katsu, T, Otsuki, T, Inoue, T, Epilepsy treatment. Targeting LDH enzymes with a stiripentol analog to treat epilepsy. Science 347 (2015), 1362–1367.
43. Li, J, O'Leary, EI, Tanner, GR, The ketogenic diet metabolite beta-hydroxybutyrate (beta-HB) reduces incidence of seizure-like activity (SLA) in a Katp- and GABAb-dependent manner in a whole-animal Drosophila melanogaster model. Epilepsy Res 133 (2017), 6–9.
44. Kobow, K, Kaspi, A, Harikrishnan, KN, et al. Deep sequencing reveals increased DNA methylation in chronic rat epilepsy. Acta Neuropathol 126 (2013), 741–756.
45. Lusardi, TA, Akula, KK, Coffman, SQ, Ruskin, DN, Masino, SA, Boison, D, Ketogenic diet prevents epileptogenesis and disease progression in adult mice and rats. Neuropharmacology 99 (2015), 500–509.
46. Tan, KN, Carrasco-Pozo, C, McDonald, TS, Puchowicz, M, Borges, K, Tridecanoin is anticonvulsant, antioxidant, and improves mitochondrial function. J Cereb Blood Flow Metab 37 (2016), 2035–2048.
47. Rogawski, MA, AMPA receptors as a molecular target in epilepsy therapy. Acta Neurol Scand Suppl 197 (2013), 9–18.
48. Haidukewych, D, Forsythe, WI, Sills, M, Monitoring octanoic and decanoic acids in plasma from children with intractable epilepsy treated with medium-chain triglyceride diet. Clin Chem 28 (1982), 642–645.
49. Rogawski, MA, Revisiting AMPA receptors as an antiepileptic drug target. Epilepsy Curr 11 (2011), 56–63.
50. Loscher, W, Critical review of current animal models of seizures and epilepsy used in the discovery and development of new antiepileptic drugs. Seizure 20 (2011), 359–368.
51. Socala, K, Nieoczym, D, Pierog, M, Wlaz, P, Role of the adenosine system and glucose restriction in the acute anticonvulsant effect of caprylic acid in the 6 Hz psychomotor seizure test in mice. Prog Neuropsychopharmacol Biol Psychiatry 57 (2015), 44–51.
52. Bough, KJ, Rho, JM, Anticonvulsant mechanisms of the ketogenic diet. Epilepsia 48 (2007), 43–58.
53. Cho, I, Hwang, GJ, Cho, JH, Uncoupling protein, UCP-4 may be involved in neuronal defects during aging and resistance to pathogens in Caenorhabditis elegans. Mol Cells 39 (2016), 680–686.
54. Chuang, YC, Lin, TK, Huang, HY, et al. Peroxisome proliferator-activated receptors γ/mitochondrial uncoupling protein 2 signaling protects against seizure-induced neuronal cell death in the hippocampus following experimental status epilepticus. J Neuroinflammation, 9, 2012, 184.
55. Ho, PW, Ho, JW, Liu, HF, et al. Mitochondrial neuronal uncoupling proteins: a target for potential disease-modification in Parkinson's disease. Transl Neurodegener, 1, 2012, 3.
56. Newell, C, Shutt, TE, Ahn, Y, et al. Tissue specific impacts of a ketogenic diet on mitochondrial dynamics in the BTBRT+tf/j mouse. Front Physiol, 7, 2016, 654.
57. Elia, M, Klepper, J, Leiendecker, B, Hartmann, H, Ketogenic diets in the treatment of epilepsy. Curr Pharm Des, 2017 published online Aug 9. DOI:10.2174/1381612823666170809101517.
58. Simeone, TA, Matthews, SA, Samson, KK, Simeone, KA, Regulation of brain PPARgamma2 contributes to ketogenic diet anti-seizure efficacy. Exp Neurol 287 (2017), 54–64.
59. Malapaka, RR, Khoo, S, Zhang, J, et al. Identification and mechanism of 10-carbon fatty acid as modulating ligand of peroxisome proliferator-activated receptors. J Biol Chem 287 (2012), 183–195.
60. Miglio, G, Rosa, AC, Rattazzi, L, Collino, M, Lombardi, G, Fantozzi, R, PPARgamma stimulation promotes mitochondrial biogenesis and prevents glucose deprivation-induced neuronal cell loss. Neurochem Int 55 (2009), 496–504.
61. Zuckermann, AM, La Ragione, RM, Baines, DL, Williams, RS, Valproic acid protects against haemorrhagic shock-induced signalling changes via PPARgamma activation in an in vitro model. Br J Pharmacol 172 (2015), 5306–5317.
62. Simeone, TA, Matthews, SA, Simeone, KA, Synergistic protection against acute flurothyl-induced seizures by adjuvant treatment of the ketogenic diet with the type 2 diabetes drug pioglitazone. Epilepsia 58 (2017), 1440–1450.
63. Kashiwaya, Y, Takeshima, T, Mori, N, Nakashima, K, Clarke, K, Veech, RL, D-beta-hydroxybutyrate protects neurons in models of Alzheimer's and Parkinson's disease. Proc Natl Acad Sci USA 97 (2000), 5440–5444.
64. Reger, MA, Henderson, ST, Hale, C, et al. Effects of beta-hydroxybutyrate on cognition in memory-impaired adults. Neurobiol Aging 25 (2004), 311–314.
65. Henderson, ST, Vogel, JL, Barr, LJ, Garvin, F, Jones, JJ, Costantini, LC, Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer's disease: a randomized, double-blind, placebo-controlled, multicenter trial. Nutr Metab (Lond), 6, 2009, 31.
66. Ohnuma, T, Toda, A, Kimoto, A, et al. Benefits of use, and tolerance of, medium-chain triglyceride medical food in the management of Japanese patients with Alzheimer's disease: a prospective, open-label pilot study. Clin Interv Aging 11 (2016), 29–36.
67. Rebello, CJ, Keller, JN, Liu, AG, Johnson, WD, Greenway, FL, Pilot feasibility and safety study examining the effect of medium chain triglyceride supplementation in subjects with mild cognitive impairment: a randomized controlled trial. BBA Clin 3 (2015), 123–125.
68. Brownlow, ML, Benner, L, D'Agostino, D, Gordon, MN, Morgan, D, Ketogenic diet improves motor performance but not cognition in two mouse models of Alzheimer's pathology. PLoS One, 8, 2013, e75713.
69. Wang, D, Govindaiah, G, Liu, R, De Arcangelis, V, Cox, CL, Xiang, YK, Binding of amyloid beta peptide to beta2 adrenergic receptor induces PKA-dependent AMPA receptor hyperactivity. FASEB J 24 (2010), 3511–3521.
70. Wisely, EV, Xiang, YK, Oddo, S, Genetic suppression of beta2-adrenergic receptors ameliorates tau pathology in a mouse model of tauopathies. Hum Mol Genet 23 (2014), 4024–4034.
71. Banke, TG, Bowie, D, Lee, H, Huganir, RL, Schousboe, A, Traynelis, SF, Control of GluR1 AMPA receptor function by cAMP-dependent protein kinase. J Neurosci 20 (2000), 89–102.
72. Whitcomb, DJ, Hogg, EL, Regan, P, et al. Intracellular oligomeric amyloid-beta rapidly regulates GluA1 subunit of AMPA receptor in the hippocampus. Sci Rep, 5, 2015, 10934.
73. Beppu, K, Kosai, Y, Kido, MA, et al. Expression, subunit composition, and function of AMPA-type glutamate receptors are changed in activated microglia; possible contribution of GluA2 (GluR-B)-deficiency under pathological conditions. Glia 61 (2013), 881–891.
74. Noda, M, Dysfunction of glutamate receptors in microglia may cause neurodegeneration. Curr Alzheimer Res 13 (2016), 381–386.
75. Rui, Y, Gu, J, Yu, K, Hartzell, HC, Zheng, JQ, Inhibition of AMPA receptor trafficking at hippocampal synapses by beta-amyloid oligomers: the mitochondrial contribution. Mol Brain, 3, 2010, 10.
76. Ikonomovic, MD, Mizukami, K, Davies, P, Hamilton, R, Sheffield, R, Armstrong, DM, The loss of GluR2(3) immunoreactivity precedes neurofibrillary tangle formation in the entorhinal cortex and hippocampus of Alzheimer brains. J Neuropathol Exp Neurol 56 (1997), 1018–1027.
77. Du, H, Guo, L, Yan, S, Sosunov, AA, McKhann, GM, Yan, SS, Early deficits in synaptic mitochondria in an Alzheimer's disease mouse model. Proc Natl Acad Sci USA 107 (2010), 18670–18675.
78. Calkins, MJ, Reddy, PH, Amyloid beta impairs mitochondrial anterograde transport and degenerates synapses in Alzheimer's disease neurons. Biochim Biophys Acta 1812 (2011), 507–513.
79. Hu, H, Li, M, Mitochondria-targeted antioxidant mitotempo protects mitochondrial function against amyloid beta toxicity in primary cultured mouse neurons. Biochem Biophys Res Commun 478 (2016), 174–180.
80. Nafar, F, Mearow, KM, Coconut oil attenuates the effects of amyloid-beta on cortical neurons in vitro. J Alzheimers Dis 39 (2014), 233–237.
81. Kanabus, M, Fassone, E, Hughes, SD, et al. The pleiotropic effects of decanoic acid treatment on mitochondrial function in fibroblasts from patients with complex I deficient Leigh syndrome. J Inherit Metab Dis 39 (2016), 415–426.
82. Sengupta, A, Ghosh, M, Comparison of native and capric acid-enriched mustard oil effects on oxidative stress and antioxidant protection in rats. Br J Nutr 107 (2012), 845–849.
83. Heneka, MT, Sastre, M, Dumitrescu-Ozimek, L, et al. Acute treatment with the PPARgamma agonist pioglitazone and ibuprofen reduces glial inflammation and Abeta1–42 levels in APPV717I transgenic mice. Brain 128 (2005), 1442–1453.
84. Warburg, O, On respiratory impairment in cancer cells. Science 124 (1956), 269–270.
85. Branco, AF, Ferreira, A, Simoes, RF, et al. Ketogenic diets: from cancer to mitochondrial diseases and beyond. Eur J Clin Invest 46 (2016), 285–298.
86. Brooks, KS, Woolf, EC, Scheck, AC, The ketogenic diet as an adjuvant therapy for brain tumors and other cancers. Ullah, MF, Ahmad, A, (eds.) Critical dietary factors in cancer chemoprevention, 2016, Springer International Publishing, Basel, 89–109.
87. Martuscello, RT, Vedam-Mai, V, McCarthy, DJ, et al. A supplemented high-fat low-carbohydrate diet for the treatment of glioblastoma. Clin Cancer Res 22 (2016), 2482–2495.
88. Choi, J, Stradmann-Bellinghausen, B, Yakubov, E, Savaskan, NE, Regnier-Vigouroux, A, Glioblastoma cells induce differential glutamatergic gene expressions in human tumor-associated microglia/macrophages and monocyte-derived macrophages. Cancer Biol Ther 16 (2015), 1205–1213.
89. Ishiuchi, S, Tsuzuki, K, Yoshida, Y, et al. Blockage of Ca(2+)-permeable AMPA receptors suppresses migration and induces apoptosis in human glioblastoma cells. Nat Med 8 (2002), 971–978.
90. von Roemeling, CA, Radisky, DC, Marlow, LA, et al. Neuronal pentraxin 2 supports clear cell renal cell carcinoma by activating the AMPA-selective glutamate receptor-4. Cancer Res 74 (2014), 4796–4810.
91. Rosche, J, Piek, J, Hildebrandt, G, Grossmann, A, Kirschstein, T, Benecke, R, Perampanel in the treatment of a patient with glioblastoma multiforme without IDH1 mutation and without MGMT promotor methylation. Fortschr Neurol Psychiatr 83 (2015), 286–289 (in German).
92. Leahy, JL, Pathogenesis of type 2 diabetes mellitus. Arch Med Res 36 (2005), 197–209.
93. St-Onge, MP, Ross, R, Parsons, WD, Jones, PJ, Medium-chain triglycerides increase energy expenditure and decrease adiposity in overweight men. Obes Res 11 (2003), 395–402.
94. Takeuchi, H, Noguchi, O, Sekine, S, Kobayashi, A, Aoyama, T, Lower weight gain and higher expression and blood levels of adiponectin in rats fed medium-chain TAG compared with long-chain TAG. Lipids 41 (2006), 207–212.
95. Whiting, S, Camfield, P, Arab, D, Salisbury, S, Insulin-dependent diabetes mellitus presenting in children as frequent, medically unresponsive, partial seizures. J Child Neurol 12 (1997), 178–180.
96. Petersen, KF, Dufour, S, Befroy, D, Garcia, R, Shulman, GI, Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes. N Engl J Med 350 (2004), 664–671.
97. Koves, TR, Ussher, JR, Noland, RC, et al. Mitochondrial overload and incomplete fatty acid oxidation contribute to skeletal muscle insulin resistance. Cell Metab 7 (2008), 45–56.
98. Houstis, N, Rosen, ED, Lander, ES, Reactive oxygen species have a causal role in multiple forms of insulin resistance. Nature 440 (2006), 944–948.
99. Mootha, VK, Lindgren, CM, Eriksson, KF, et al. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet 34 (2003), 267–273.
100. Yuen, AWC, Walcutt, IA, Sander, JW, An acidosis-sparing ketogenic (ASK) diet to improve efficacy and reduce adverse effects in the treatment of refractory epilepsy. Epilepsy Behav 74 (2017), 15–21.